NEW YORK (GenomeWeb) – Rosetta Genomics today announced that it has signed a deal to promote Precipio Diagnostics' oncology tests in certain US states, with plans to expand nationally later on.
Through a network of collaborations with Yale School and Medicine and other academic institutes, New Haven, Conn.-based Precipio offers a suite of molecular diagnostics that it tailors to patients' disease based on pathology and symptoms.
Under the agreement, Rosetta will promote Precipio's tests, including ones based on bone marrow and peripheral blood for hematologic cancers in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia, and Washington, DC, with an eye toward expanding nationally.
Rosetta said that the partnership is expected to help raise awareness about its own Cancer Origin Test, which analyzes patients' microRNA expression signatures to identify the source of cancers of unknown primary origin.
"We will promote the Precipio diagnostic services to the same doctors who also struggle with patients without a definitive diagnosis as to their cancers’ origin, which hampers decisions regarding optimal therapeutic approach," Rosetta President and CEO Kenneth Berlin said in a statement. "This partnership … allows us to provide more complete solutions for our customers and to optimize our commercial infrastructure."
Financial terms of the arrangement were not disclosed.